molecules of the month


oral, selective beta-catenin/CBP PPI inhibitor

synergy w/ PD-1i in model, in Ph. I for cancer

opt. of prior peptidomimetic candidate

Cancer Res., Jan. 6, 2021

Eisai Co., Ltd., Tsukuba, JP

Chemical structure of molecule E7386 modulator
1 min read

The Eisai β-catenin/CBP inhibitor, E7386, is an orally active and selective inhibitor of the β-catenin/CBP protein-protein interaction, a key node in the long studied Wnt/β-catenin pathway in cancer. Prior attempts to drug Wnt directly were met with severe toxicity in clinical trials. The pathway has seen a resurgence in interest due to its potential role in tumor immune evasion, and the Eisei team demonstrates that E7386 synergizes with anti-PD-1 in a syngeneic model. E7386 is currently in a Ph. I study as a monotherapy for solid tumors.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: